What Bears Saw Before Afya Slid

If you backed Afya for its role in training doctors and building out Brazil’s digital health infrastructure, the payoff over this stretch was painful. For Afya shareholders, the loss from the start of the year was 25.7%, including dividends. If you had bought in on 1 January believing that physician shortages, an aging population and digital health adoption would drive sustained growth and margin expansion, what did that original thesis fail to factor in?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

The move put Afya in the middle of this trade. Scan 34 healthcare AI stocks for other companies exposed to it.

The Two Afya Stories Investors Were Choosing Between

The shares cost US$15.41 at the start of the period, and Afya sat between two sharply different stories that both sounded reasonable at the time.

On the optimistic side, the bull Narrative put Fair Value at US$25.04, 62% above the start price, assuming Brazil's physician shortage and digital health penetration would support sustained revenue growth and a move in profit margins from 19.6% to 32.3% by about 2028.

The bear Narrative saw Fair Value at US$14.09, 9% below the start price, arguing that AI powered medical education, macro instability in Brazil, and accredited online competitors could cap enrollment growth and weaken Afya's pricing power.

What The Afya Results Actually Put To The Test

The binding merger agreement with Yduqs gave Afya fresh scale potential that backed parts of the bullish consolidation story, while also confirming the bear worry that competition was intense enough to push educators together. Reported Q2 2026 figures showed revenue at R$972.1m, net income at R$197.1m and net margin rising to 20.3%, which still sat a long way from the 32.3% margin the optimistic case imagined.

The lesson is simple. When a thesis hangs on margin expansion and consolidation, treat both as testable claims. Track reported net margin against the original target and watch whether mergers move from early talks to binding deals with clear terms and disclosed integration risks.

What Afya's Lower Price Now Asks You To Believe

Afya trades today at US$10.64, well below where the year began, while the selected Narrative’s Fair Value sits above the current price based on its own assumptions rather than hard fact.

The lens has shifted to whether scale from the planned Yduqs merger and pricing power in premium medical courses can offset tax, competition and digital product pressure. For the fall to look like an opening instead of a warning, a buyer would need to believe the Afya and Yduqs integration achieves the stated cost synergies without eroding earnings quality.

"The planned merger between Afya and Yduqs, with an expected BRL 2.0b to 2.2b in cost synergies and a combined revenue base of about BRL 9.5b, could materially increase scale and operating efficiency, which would support higher net margins and earnings over time."

One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all

Find Your Own Contrarian Opportunity

This company's disappointment is already part of the story. Your next idea could come from looking where the price and the possibilities still seem far apart. Here are three companies priced below our estimates.

• Company 1 - 44% below our estimate - supply solar tracking and control equipment as customers integrate storage, inverters and software.
• Company 2 - 41% below our estimate - target large-scale LED projects as software, services and process changes reshape cost structures.
• Company 3 - 48% below our estimate - convert a sizeable construction backlog and mega projects into cash while managing contract disputes.

That is three of the list. See every one of the 29 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com